Why the study?
Does nebivolol improve large artery compliance compared to metoprolol succinate in patients with type 2 diabetes and hypertension on maximal RAS blockade?
Does nebivolol improve large artery compliance compared to metoprolol succinate in patients with type 2 diabetes and hypertension on maximal RAS blockade?
In patients with type 2 diabetes and hypertension on maximal RAS blockade, nebivolol does not significantly reduce aortic BP more than metoprolol succinate, but it maintains a more stable metabolic profile.
No takes yet. Share an insight, caveat, or question.
Nebivolol offers no arterial compliance advantage over metoprolol; extends evidence supporting its preference for metabolic stability in diabetic hypertension.
Briasoulis et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: